169 related articles for article (PubMed ID: 37929279)
1. Genetic analysis of the equine orthologues for human CYP2D6: unraveling the complexity of the CYP2D family in horses.
Scantamburlo G; Nofziger C; Paulmichl M; Vanoni S
Front Vet Sci; 2023; 10():1188633. PubMed ID: 37929279
[TBL] [Abstract][Full Text] [Related]
2. Complementary DNA cloning, functional expression and characterization of a novel cytochrome P450, CYP2D50, from equine liver.
DiMaio Knych HK; Stanley SD
Biochem Pharmacol; 2008 Oct; 76(7):904-11. PubMed ID: 18692486
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the in vitro CYP450 mediated metabolism of the polymorphic CYP2D6 probe drug codeine in horses.
Knych HK; Baden RW; Gretler SR; McKemie DS
Biochem Pharmacol; 2019 Oct; 168():184-192. PubMed ID: 31295464
[TBL] [Abstract][Full Text] [Related]
4. Evidence for polymorphism in the cytochrome P450 2D50 gene in horses.
Corado CR; McKemie DS; Young A; Knych HK
J Vet Pharmacol Ther; 2016 Jun; 39(3):245-54. PubMed ID: 26441153
[TBL] [Abstract][Full Text] [Related]
5. Functional phenotyping of the CYP2D6 probe drug codeine in the horse.
Gretler SR; Finno CJ; Kass PH; Knych HK
BMC Vet Res; 2021 Feb; 17(1):77. PubMed ID: 33581736
[TBL] [Abstract][Full Text] [Related]
6. A Comparison of Non-Human Primate Cytochrome P450 2D Members and the Implication in Drug Discovery.
He ZX; Chen XW; Yang Y; Zhou SF
Curr Drug Metab; 2016; 17(6):520-7. PubMed ID: 26892731
[TBL] [Abstract][Full Text] [Related]
7. Dextromethorphan and debrisoquine metabolism and polymorphism of the gene for cytochrome P450 isozyme 2D50 in Thoroughbreds.
Corado CR; McKemie DS; Knych HK
Am J Vet Res; 2016 Sep; 77(9):1029-35. PubMed ID: 27580115
[TBL] [Abstract][Full Text] [Related]
8. Human CYP2D6 Is Functional in Brain In Vivo: Evidence from Humanized CYP2D6 Transgenic Mice.
Tolledo C; Stocco MR; Miksys S; Gonzalez FJ; Tyndale RF
Mol Neurobiol; 2020 Jun; 57(6):2509-2520. PubMed ID: 32189192
[TBL] [Abstract][Full Text] [Related]
9. Human CYP2D6 and mouse CYP2Ds: organ distribution in a humanized mouse model.
Miksys SL; Cheung C; Gonzalez FJ; Tyndale RF
Drug Metab Dispos; 2005 Oct; 33(10):1495-502. PubMed ID: 16033950
[TBL] [Abstract][Full Text] [Related]
10. Comparative human-horse sequence analysis of the CYP3A subfamily gene cluster.
Schmitz A; Demmel S; Peters LM; Leeb T; Mevissen M; Haase B
Anim Genet; 2010 Dec; 41 Suppl 2():72-9. PubMed ID: 21070279
[TBL] [Abstract][Full Text] [Related]
11. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine.
Johansson I; Lundqvist E; Bertilsson L; Dahl ML; Sjöqvist F; Ingelman-Sundberg M
Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11825-9. PubMed ID: 7903454
[TBL] [Abstract][Full Text] [Related]
12. Evolution of the CYP2D gene cluster in humans and four non-human primates.
Yasukochi Y; Satta Y
Genes Genet Syst; 2011; 86(2):109-16. PubMed ID: 21670550
[TBL] [Abstract][Full Text] [Related]
13. Regional and cellular distribution of CYP2D subfamily members in rat brain.
Miksys S; Rao Y; Sellers EM; Kwan M; Mendis D; Tyndale RF
Xenobiotica; 2000 Jun; 30(6):547-64. PubMed ID: 10923858
[TBL] [Abstract][Full Text] [Related]
14. Propranolol is a mechanism-based inhibitor of CYP2D and CYP2D6 in humanized CYP2D6-transgenic mice: Effects on activity and drug responses.
Tolledo EC; Miksys S; Gonzalez FJ; Tyndale RF
Br J Pharmacol; 2020 Feb; 177(3):701-712. PubMed ID: 31648367
[TBL] [Abstract][Full Text] [Related]
15. Characterization of complex structural variation in the
Turner AJ; Derezinski AD; Gaedigk A; Berres ME; Gregornik DB; Brown K; Broeckel U; Scharer G
Front Pharmacol; 2023; 14():1195778. PubMed ID: 37426826
[TBL] [Abstract][Full Text] [Related]
16. Equine cytochrome P450 2B6--genomic identification, expression and functional characterization with ketamine.
Peters LM; Demmel S; Pusch G; Buters JT; Thormann W; Zielinski J; Leeb T; Mevissen M; Schmitz A
Toxicol Appl Pharmacol; 2013 Jan; 266(1):101-8. PubMed ID: 23142468
[TBL] [Abstract][Full Text] [Related]
17. Identification of subtypes of CYP2D gene rearrangements among carriers of CYP2D6 gene deletion and duplication.
Ledesma MC; Agúndez JA
Clin Chem; 2005 Jun; 51(6):939-43. PubMed ID: 15817819
[TBL] [Abstract][Full Text] [Related]
18. The roles of Cyp1a2 and Cyp2d in pharmacokinetic profiles of serotonin and norepinephrine reuptake inhibitor duloxetine and its metabolites in mice.
Qin X; Xie C; Hakenjos JM; MacKenzie KR; Boyd SR; Barzi M; Bissig KD; Young DW; Li F
Eur J Pharm Sci; 2023 Feb; 181():106358. PubMed ID: 36513193
[TBL] [Abstract][Full Text] [Related]
19. The Involvement of PPARs in the Selective Regulation of Brain CYP2D by Growth Hormone.
Zhang F; Li J; Na S; Wu J; Yang Z; Xie X; Wan Y; Li K; Yue J
Neuroscience; 2018 May; 379():115-125. PubMed ID: 29555426
[TBL] [Abstract][Full Text] [Related]
20. Catalytic specificity of CYP2D isoforms in rat and human.
Hiroi T; Chow T; Imaoka S; Funae Y
Drug Metab Dispos; 2002 Sep; 30(9):970-6. PubMed ID: 12167561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
